Australian experience shows EU IVD transition period must not be shorter than five years
This article was originally published in SRA
Experience with the implementation of new in vitro diagnostics regulations in Australia suggests that the EU is going to need a five-year transition period to ensure that all stakeholders are in a position to fully comply with anticipated new requirements1. That is the view of Jesús Rueda Rodríguez, regulatory affairs director at the European Diagnostic Manufacturers Association.
You may also be interested in...
Interview: Bassil Akra Speaks About Leaving TÜV-SÜD, Future Challenges, Opportunities And COVID-19 Realities
As Bassil Akra returned his office equipment and access card to his TÜV-SÜD offices in Munich amidst a welcome of balloons, Medtech Insight asked what this meant for him personally and what it will be like to start in consultancy during a pandemic.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.
National authorities can renew notified body designations by conducting reviews that do not include on-site visits, overturning one of the most critical measures introduced in medical device regulations over the last seven years.